- Home
- RXST
RXST
RxSight Inc.
as 07-26-2024 4:00pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 2.2B | IPO Year: | 2021 |
| Target Price: | $65.14 | AVG Volume (30 days): | 678.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.66 - $66.54 | Next Earning Date: | 08-05-2024 |
| Revenue: | $101,101,000 | Revenue Growth: | 75.67% |
| Revenue Growth (this year): | 54.66% | Revenue Growth (next year): | 33.24% |
Stock Insider Trading Activity of RxSight Inc. (RXST)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thunen Shelley B | RXST | Chief Financial Officer | Jul 1 '24 | Sell | $59.56 | 1,803 | $107,394.07 | 0 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Jul 1 '24 | Sell | $58.55 | 6,599 | $386,366.17 | 1,803 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Jul 1 '24 | Sell | $59.48 | 1,854 | $110,270.36 | 13,938 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Jul 1 '24 | Sell | $58.41 | 8,146 | $475,785.05 | 15,792 | SEC Form 4 |
| Andrews Julie | RXST | Director | Jun 14 '24 | Sell | $58.53 | 3,685 | $215,679.73 | 30,287 | SEC Form 4 |
| Andrews Julie | RXST | Director | Jun 14 '24 | Sell | $57.84 | 11,940 | $690,608.41 | 33,972 | SEC Form 4 |
| Tammenoms Bakker Juliet | RXST | Director | May 17 '24 | Buy | $61.09 | 5,000 | $305,456.50 | 34,840 | SEC Form 4 |
| Kurtz Ronald M MD | RXST | President & CEO | May 3 '24 | Sell | $60.15 | 40,000 | $2,405,872.00 | 764,610 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | May 1 '24 | Sell | $52.68 | 9,620 | $506,758.51 | 14,318 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | May 1 '24 | Sell | $53.04 | 380 | $20,154.21 | 13,938 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Apr 1 '24 | Sell | $49.81 | 8,857 | $441,207.03 | 19,545 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Apr 1 '24 | Sell | $50.27 | 800 | $40,218.00 | 18,745 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Apr 1 '24 | Sell | $49.81 | 8,938 | $445,225.02 | 9,807 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Apr 1 '24 | Sell | $50.24 | 662 | $33,257.69 | 9,145 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Apr 1 '24 | Sell | $50.37 | 200 | $10,074.00 | 8,945 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Apr 1 '24 | Sell | $51.50 | 543 | $27,964.50 | 8,402 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Mar 1 '24 | Sell | $54.95 | 1,166 | $64,065.87 | 22,525 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Mar 1 '24 | Sell | $56.38 | 6,361 | $358,617.91 | 16,164 | SEC Form 4 |
| Thunen Shelley B | RXST | Chief Financial Officer | Mar 1 '24 | Sell | $57.03 | 2,473 | $141,041.87 | 13,691 | SEC Form 4 |
| Goldshleger Ilya | RXST | Chief Operating Officer | Feb 14 '24 | Sell | $56.00 | 5,000 | $280,000.00 | 26,475 | SEC Form 4 |
| Goldshleger Ilya | RXST | Chief Operating Officer | Feb 14 '24 | Sell | $55.00 | 5,000 | $275,000.00 | 31,475 | SEC Form 4 |
| Goldshleger Ilya | RXST | Chief Operating Officer | Feb 14 '24 | Sell | $54.00 | 5,000 | $270,000.00 | 26,475 | SEC Form 4 |
| Goldshleger Ilya | RXST | Chief Operating Officer | Feb 14 '24 | Sell | $53.00 | 5,000 | $265,000.00 | 31,475 | SEC Form 4 |
| Goldshleger Ilya | RXST | Chief Operating Officer | Feb 14 '24 | Sell | $52.00 | 5,000 | $260,000.00 | 26,475 | SEC Form 4 |
| Tammenoms Bakker Juliet | RXST | Director | Feb 12 '24 | Buy | $50.38 | 4,000 | $201,519.60 | 25,840 | SEC Form 4 |
Latest RxSight Inc. News
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exploring Undervalued Small Caps With Insider Action In The United States July 2024
GlobeNewswire
4 days ago
RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
Zacks
14 days ago
RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Investor's Business Daily
16 days ago
Dow Jones Jumps 429 Points On Fed Chief's Comments; Gold Miners, Chips Rally (Live Coverage)
MT Newswires
16 days ago
Stifel Adjusts Price Target on RxSight to $70 From $75, Maintains Buy Rating
Simply Wall St.
a month ago
Institutional investors control 71% of RxSight, Inc. (NASDAQ:RXST) and were rewarded last week after stock increased 6.0%
MT Newswires
a month ago
RxSight Insider Sold Shares Worth $906,288, According to a Recent SEC Filing
GuruFocus.com
a month ago
Insider Sale: Director Julie Andrews Sells 15,625 Shares of RxSight Inc (RXST)
Compare RXST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.